The opportunities for elimination of hepatitis C virus (HCV) have been transformed by advances in diagnosis and treatment including price reductions. However, achieving the 2030 coverage targets of 90% diagnosis and 80% treatment of those infected seems remote. In 2017, only 20% of people with HCV were tested and ~25% of those diagnosed were treated. As for HIV, there is a need for continued simplification of care pathway to promote access to HCV services. This session will highlight key results from a three year Unitaid-funded project in four countries with policy implications and lessons learned. The interventions assessed include decentralized HCV testing, care and treatment in primary care, at antiretroviral therapy (ART) and harm-reduction sites (HRS); use of point-of-care HCV viral load at HRS for people who inject drugs (PWID) and ART clinics for people living with HIV (PLHIV); and first results on use of HCV self-testing in three countries.